Please use this identifier to cite or link to this item:
Title: Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin
Author: Sicras Mainar, Antoni
Rejas, Javier
Pérez-Paramo, Maria
Sánchez-Álvarez, Luis
Navarro-Artieda, Ruth
Darbà, Josep
Keywords: Medicaments
Medicaments genèrics
Anàlisi cost-benefici
Tractament del dolor
Generic drugs
Cost effectiveness
Pain treatment
Issue Date: Feb-2019
Publisher: Informa Healthcare
Abstract: Background: Discrepancies are seen between arguments in favor of and against prescribing generic versus brand-name drugs. Objective: To provide real-world evidence on treatment persistence, economic and clinical outcomes of pregabalin, generic versus brand-name (Lyrica®, Pfizer), routinely used to treat neuropathic pain (NP) or generalized anxiety disorder (GAD). Methods: Electronic medical records from subjects' first starting treatment with pregabalin between January-2015 and June-2016 were analyzed. Persistence, resources utilization, and costs were assessed, along with remitter and responder rates. (...)
Note: Versió postprint del document publicat a:
It is part of: Expert Review of Pharmacoeconomics & Outcomes Research, 2019, vol. 19, num. 1, p. 45-57
Related resource:
ISSN: 1473-7167
Appears in Collections:Articles publicats en revistes (Economia)

Files in This Item:
File Description SizeFormat 
686010.pdf449.11 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.